Blood News and Research

RSS

Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO

Nektar Therapeutics today announced that results from the Phase 2 clinical trial of NKTR-102 in women with platinum-resistant/refractory ovarian cancer will be presented at the Oral Abstract Session of the Gynecologic Cancer Track during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

21 May 2010

Cord Blood America reviews first quarter results

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that its co-founder and CEO, Matthew Schissler, reviewed first quarter results and progress in an interview with analyst Francis Gaskins.

21 May 2010

New research seeks customised treatment of cardiovascular diseases

The Centre for Cooperative Research in Biomaterials, CIC biomaGUNE, is involved in the research consortium of cvREMOD, which aims to move forward in the attainment of new diagnosis techniques for prevention and customised treatment of cardiovascular diseases in the upcoming four years.

21 May 2010

Restoration of post-meal blood vessel expansion may help improve strength and health in elderly people

Why do people become physically weaker as they age? And is there any way to slow, stop, or even reverse this process, breaking the link between increasing age and frailty?

21 May 2010

Transplant centers should utilize DCD kidneys to minimize patients’ mortality rates

In the United States over 80,000 people are on the kidney transplant waiting list, and thousands die each year waiting for transplants. For most dialysis patients, kidney transplantation increases their chances of survival.

21 May 2010

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, will present data from three Phase II clinical trials highlighting the clinical potential of its unique phosphatidylserine -targeting antibody bavituximab for the treatment of solid tumors.

21 May 2010

New clinical procedures, better diagnostics improve prognosis for children born with severe acute asphyxia

The prognosis for children born with severe acute asphyxia has improved in recent years owing to new clinical procedures and better diagnostics, according to a new doctoral thesis from the Swedish medical university Karolinska Institutet. By measuring levels of lactic acid in the blood during childbirth and the brain activity of the newborn afterwards, doctors can make a much more reliable assessment of the risk of serious brain damage.

21 May 2010

Vitamin D plays much wider role in people's life

Vitamin D is the sunshine vitamin - we make it when our skin is exposed to UV rays. In a perfect world everyone would eat fresh, organic foods, get outside, and enjoy a little sunshine all year round. But with today's busy lifestyles and concerns about skin cancer many people are vitamin D deficient and don't know it.

21 May 2010

Majority of patients satisfied with care, but doctors lack multicultural awareness

Most patients in the southeastern United States are satisfied with the care they get from their primary care doctor — though many doctors lack training for dealing with patients of different ethnic backgrounds and often fail to ask important questions that indicate multicultural awareness, according to results of two surveys presented at the American Heart Association's 11th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke.

21 May 2010

Phase III PRIMA study data of Rituxan to be featured at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec today announced data from the Phase III PRIMA study.

21 May 2010

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Results of two Phase II trials evaluating ALIMTA (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung cancer will be presented by Eli Lilly and Company at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago, Ill., on June 6, 2010.

21 May 2010

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

Lilly released results today from a Phase II study evaluating Lilly Oncology's tasisulam, a novel anti-cancer agent, in patients with metastatic melanoma, the deadliest form of skin cancer. Study results will be presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. on June 6, 2010.

21 May 2010

Hepatitis C affects so many people and yet not recognized as serious public health problem

May is Hepatitis Awareness Month, and you may find it surprising to learn an estimated 4 million Americans have been infected with Hepatitis C. This silent disease is three to five times more prevalent than HIV. Hepatitis C is the most common cause of liver transplants in the U.S.

21 May 2010

HemaCare announces commercial cell therapy collection agreement with Dendreon

HemaCare Corporation today announced an agreement with Dendreon Corporation to provide cellular collection services in Los Angeles and Maine for their new autologous cellular immunotherapy, PROVENGE® (sipuleucel-T). This personalized medicine is Dendreon's lead product and is the first autologous cellular immunotherapy specifically designed to engage patients' own immune systems to treat cancer.

21 May 2010

SLU Hospital announces increase in number of minimally-invasive spinal procedures performed

With the recent launch of the Neurosurgical Spine Program at Saint Louis University Hospital's Center for Cerebrovascular and Skull Base Surgery, the hospital has seen a dramatic increase in the number of minimally-invasive spinal procedures, including lumbar spinal fusion surgery. Designed to stop the motion at a painful vertebral segment, this procedure is traditionally performed via a large incision on the back, stripping vital muscles away from the spine. However, the emergence of minimally-invasive neurosurgical techniques is revolutionizing spinal surgery.

21 May 2010

Blood clot-related strokes decrease among whites for the first time: Study

The incidence of blood clot-related strokes fell among whites in the Greater Cincinnati/Northern Kentucky area for the first time, according to long-term surveillance study representative of strokes in blacks and whites nationwide reported in Stroke: Journal of the American Heart Association.

21 May 2010

Biocept granted US patent for cell separation technology using microfluidic device

Biocept, Inc., an emerging leader in rare cell capture, announced today that the U.S. Patent and Trademark Office has issued a patent for Biocept's cell separation technology using a microfluidic device. U.S. patent #7,695,956 entitled "Device for Cell Separation and Analysis and Method of Using" protects Biocept's microflow device to isolate cells from a bodily fluid using a flow path where straight-line flow is interrupted by transverse posts arranged in a random pattern.

21 May 2010

Vascular Insights wins CE Mark approval for ClariVein Occlusion Catheter

Vascular Insights announced today that it has won approval for use of the CE Mark on its ClariVein® Occlusion Catheter, paving the way for marketing of the device in Europe.

21 May 2010

New study reveals PTPN2 gene loss causes bone cancer

In patients with leukemia, the formation of white blood cells in the bone marrow is disrupted. This makes leukemia patients particularly susceptible to infections, because properly functioning white blood cells ensure protection against intruders such as viruses and bacteria.

21 May 2010

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Researchers at Columbia University recently analyzed the positive effects of Modified Citrus Pectin (MCP) on human and mouse prostate cancer cell lines. The results, as reported by lead researcher Dr. Aaron Katz in the online-first publication of Integrative Cancer Therapies, show that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and androgen-independent cancer cells in a time and dose-dependent manner.

20 May 2010

Blood News and Research

Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO

Cord Blood America reviews first quarter results

New research seeks customised treatment of cardiovascular diseases

Restoration of post-meal blood vessel expansion may help improve strength and health in elderly people

Transplant centers should utilize DCD kidneys to minimize patients’ mortality rates

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

New clinical procedures, better diagnostics improve prognosis for children born with severe acute asphyxia

Vitamin D plays much wider role in people's life

Majority of patients satisfied with care, but doctors lack multicultural awareness

Phase III PRIMA study data of Rituxan to be featured at 46th ASCO

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

Hepatitis C affects so many people and yet not recognized as serious public health problem

HemaCare announces commercial cell therapy collection agreement with Dendreon

SLU Hospital announces increase in number of minimally-invasive spinal procedures performed

Blood clot-related strokes decrease among whites for the first time: Study

Biocept granted US patent for cell separation technology using microfluidic device

Vascular Insights wins CE Mark approval for ClariVein Occlusion Catheter

New study reveals PTPN2 gene loss causes bone cancer

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News